Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates …

Over the past decades, immunotherapy has demonstrated a prominent clinical efficacy in a
wide variety of human tumors. For many years, apoptosis has been considered a non …

Cell surface expression levels of GPRC5D, an orphan G protein–coupled receptor, are
significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or …

Background Multiple myeloma is an incurable plasma cell malignancy that is mostly
restricted to the bone marrow. Cancer-induced dysfunction of cytotoxic T cells at the tumor …

CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of
migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed …

Harnessing the power of the immune system to recognize and eliminate cancer cells is a
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …

Abstract Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune
evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody …

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme
CD38, a protein highly expressed on hematological malignant cells, including those in …

All cases of multiple myeloma (MM) are preceded by precursor states termed monoclonal
gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). Genetic …

Although survival of multiple myeloma patients has at least doubled during recent years,
most patients eventually relapse, and treatment at this stage may be particularly complex. At …